| Literature DB >> 36187493 |
Xin Yu1, Yuli Cui1, Xueqing Zhu1, Hongjun Xu1, Linfeng Li1, Guangcheng Gao1.
Abstract
Vitiligo is an autoimmune skin disease characterized by presence of pale patchy areas of depigmentation. MicroRNAs (miRNAs) are important regulators of gene expression and play significant roles in diverse biological and pathological processes. Accumulating evidence has shown that miRNAs were differentially expressed in skin lesions and peripheral blood mononuclear cells of patients with vitiligo. In particular, miRNAs are significantly correlated with the development and progression of vitiligo. The abundance of some miRNAs in serum was also correlated with the vitiligo lesion severity, indicating that miRNAs might serve as prognostic biomarkers. Importantly, the direct involvement of miRNAs in the pathogenesis of vitiligo has been demonstrated. For example, increased expression of miR-25 contributes to vitiligo through promoting the dysfunction and oxidative stress-induced destruction of melanocytes. However, there are limited studies on the function and mechanism of deregulated miRNAs in vitiligo. Further studies are required to establish clinical applications of miRNAs for vitiligo. More in-depth investigations of miRNAs are needed for the understanding of the pathogenesis of vitiligo and the development of novel therapeutic targets. This present review summarizes the current literature on the deregulation and pathogenic roles of miRNAs in vitiligo. We also highlight the potential clinical applications of miRNAs in patients with vitiligo.Entities:
Keywords: MiR-25; MicroRNAs; miRNA; pathogenesis; vitiligo
Year: 2022 PMID: 36187493 PMCID: PMC9523438 DOI: 10.3389/fcell.2022.964982
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
miRNAs expression profiles in vitiligo.
| Method | Sample | Up | Down | Ref | |
|---|---|---|---|---|---|
| 1 | Microarray RT-PCR | Serum of vitiligo mice | 3 miRNAs: miR-146a, miR-191, miR-342-3p | 28 | |
| 2 | Microarray RT-PCR | Serum of NSV patients | 17 miRNAs: miR-16, miR-451, miR-223, miR-19b, miR-151-5p, miR-25, miR-186, miR-195, miR-590-5p, miR-19a, miR-30days, miR-192, miR-222, miR-93, miR-146a, miR-29a, miR-191 | 14 miRNAs miR-1274A, miR-574-3p, miR-1290, miR-720,miR-10a, miR-483-5p, miR-125b, miR-150, miR-139-5p, miR-26a, let-7days, miR-30b,miR-30c, miR-126 | 33 |
| 3 | RT-PCR | Skin lesion from aNSGV vs tNSGV | 7 miRNAs miR-10a, miR-16, miR-125a, miR-139, miR-145, miR-191, miR-574 | miR-21, miR-31, miR-192 | 34 |
| PBMCs of NSGV patient vs. healthy controls | 12 miRNAs: miR-10a, miR-16, miR-21, miR-31, miR-125a, miR-139, miR-145, miR-146a, miR-181a1, miR-191, miR-192, miR-203 | ||||
| 4 | Microarray RT-PCR | Skin lesions of NSV patients compared with healthy skin from controls | 12 miRNAs: miR-1, miR-133b, miR-135a miR-183, miR-190, miR-214, miR-301b, miR-30a-3p, miR-375, miR-487a, miR-517c, miR-616 | 1 miRNAs miR-211 | 35 |
| Skin lesions of NSV patients compared with nonlesional skin | miR-136, miR- 296 and miR-328 | ||||
| 5 | Microarray | Lesional epidermal skin in vitiligo patients | 56 miRNAs | 36 | |
| 6 | Microarray RT-PCR | PBMCs of NSV patients | 2 miRNAs: miR-224-3p, miR-4712-3p | 1 miRNAs miR-3940-5p | 37 |
| 7 | RNA-seq | PBMCs of NSV patients | 223 miRNAs, Top 10: miR-335-5p, miR-20a-5p, miR-514a-3p, miR-144-5p, miR-450b-5p, miR-369-3p, miR-101-3p, miR-142-5p, miR-19b-3p, and miR-340-5p | 100 miRNAs, Top 10: miR-4443, miR-1248, miR-6859-3p, miR-668-3p, miR-7704, miR-323a-5p, miR- 1237-3p, miR-3127-3p, miR-6735-3p, and miR-127-3p | 38 |
FIGURE 1Functional roles of specific deregulated miRNAs in the cell apotosis, melanin synthesis and cell migration in vitiligo.
Functional characterization of the miRNAs in vitiligo.
| miRNAs | Expression | Functional role | Related gene | Role | Ref |
|---|---|---|---|---|---|
| miR-9 | Up | Inhibits migration of PIG1 cells to HaCaT | E-cadherin and β1 integrin | damage | 38 |
| miR-21-5p | Down | Inhibits melanocyte apoptosis | STAT3 | protect | 39 |
| miR-25 | Up | Promotes melanocyte degeneration | MITF | damage | 41 |
| miR-133 | Up | - | IL17 A/F | - | 23 |
| miR-135a | Up | Promotes melanocyte destruction | SIRT1 | damage | 33 |
| miR-145 | Down | Perinuclear accumulation of melanosomes with hypopigmentation | Myo5a | protect | 52 |
| miR-155 | Up | Inhibits melanocyte proliferation. Promotes apoptosis | MITF | damage | 42, 43 |
| MiR-183-5p | Up | - | MITF | - | 53 |
| miR-196a-2 | Polymorphisms | Inhibits melanocyte apoptosis | TYRP1 | protect | 47 |
| miR-200c | Down | Promotes melanin synthesis | SOX1 | protect | 28 |
| miR-211 | Down in UVB-treated melanocytes | Inhibits UVB-induced melanocyte migration | MMP9, SIRT1, TGF beta receptor 2 | damage | 36, 49 |
| miR-330-50 | Up | Inhibits melanin levels | TYR | damage | 55 |
| miR-377 | Up | - | PPAR-γ | - | 51 |
| miR-493-3p | Up | Promotes melanocyte apoptosis, Inhibits melanocyte proliferation and melanin synthesis | hnRNPU | damage | 27 |
| miR-2909 | Up | Inhibits melanin synthesis | MITF, TYR, TYRP1, TYRP2 | damage | 54 |